We are creating some awesome events for you. Kindly bear with us.

Revolutionary mRNA therapies in the pipeline from University of Queensland

A pilot facility at The University of Queensland could be producing mRNA vaccines and cancer therapies for research and development within months after receiving backing from the Australian Government. UQ’s Australian Institute for Bioengineering and Nanotechnology (AIBN) will host the “BASE” facility, via a $2.2 million investment of matched funds from the National Collaborative Research Infrastructure Strategy (NCRIS) through Therapeutic Innovation Australia (TIA), and the University.

The TIA CEO Dr Stuart Newman said that this support would enable the facility to produce high-quality, high-purity nucleic acids – RNA and DNA – to support the work of nucleic acid researchers across the country. “This investment complements recent investments in later-stage, large-scale mRNA manufacturing, as well as TIA’s own ongoing investment in biologics production to support R&D,” Dr Newman said.

BASE harnesses the collective UQ expertise of the leading RNA research by Associate Professor Timothy Mercer, the biomanufacturing powerhouse National Biologics Facility led by Professor Trent Munro, and the RNA and DNA production expertise of the Protein Expression Facility, led by Professor Linda Lua.

Dr Mercer said the pandemic response had demonstrated that mRNA vaccines can be quickly designed to protect against new variants and other emerging diseases.  “mRNA vaccines have been key in our fight against COVID-19, while other mRNA vaccines are showing great potential in the fight against cancer.”

Professor Munro said the facility would provide an important connection between R&D organisations and large-scale manufacturers seeking to work with the ‘revolutionary’ technologies. “It is vital that Australia develops sovereign capability in the pre-clinical synthesis of RNA and DNA to support early-stage R&D by Australian researchers and the biotechnology industry,” Professor Munro said. “TIA has recognised this growing demand and made a targeted investment in building capability, and we will now be seeking further investment to expand the services we can offer in this space.”

Professor Lua said the federal investment builds on the broad range of advanced biomanufacturing experience at UQ. “The production of large quantities of highly pure RNA and DNA for rapid response is challenging, and requires advanced equipment and a skilled team of scientists – we are delighted to team with BASE to advance research into this emerging area,” Professor Lua said.

The Queensland Department of Environment and Science said UQ’s demonstrated experience in vaccine development and infectious disease research made it the perfect location to ensure that all Australians can benefit from this important facility.

The facility will benefit from AIBN’s development of new nanoparticles –  ‘nanocontainers’ that deliver nucleic acids to their target in the cell, similar to those used in the Pfizer and Moderna vaccines. It is also envisioned that BASE will work collaboratively with other related facilities nationally, including UNSW Sydney, which has particular strengths in nanoparticle delivery systems targeting cancer and RNA chemistry.

Dr Mercer said that mRNA vaccines work by prompting our cells to make proteins that induce an immune response and cause the body to produce antibodies. “They also encode small proteins expressed by cancerous cells, allowing immune cells to recognise and attack tumours.”

PARTNER

Qlik’s vision is a data-literate world, where everyone can use data and analytics to improve decision-making and solve their most challenging problems. A private company, Qlik offers real-time data integration and analytics solutions, powered by Qlik Cloud, to close the gaps between data, insights and action. By transforming data into Active Intelligence, businesses can drive better decisions, improve revenue and profitability, and optimize customer relationships. Qlik serves more than 38,000 active customers in over 100 countries.

PARTNER

CTC Global Singapore, a premier end-to-end IT solutions provider, is a fully owned subsidiary of ITOCHU Techno-Solutions Corporation (CTC) and ITOCHU Corporation.

Since 1972, CTC has established itself as one of the country’s top IT solutions providers. With 50 years of experience, headed by an experienced management team and staffed by over 200 qualified IT professionals, we support organizations with integrated IT solutions expertise in Autonomous IT, Cyber Security, Digital Transformation, Enterprise Cloud Infrastructure, Workplace Modernization and Professional Services.

Well-known for our strengths in system integration and consultation, CTC Global proves to be the preferred IT outsourcing destination for organizations all over Singapore today.

PARTNER

Planview has one mission: to build the future of connected work. Our solutions enable organizations to connect the business from ideas to impact, empowering companies to accelerate the achievement of what matters most. Planview’s full spectrum of Portfolio Management and Work Management solutions creates an organizational focus on the strategic outcomes that matter and empowers teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enables customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, with locations around the world, Planview has more than 1,300 employees supporting 4,500 customers and 2.6 million users worldwide. For more information, visit www.planview.com.

SUPPORTING ORGANISATION

SIRIM is a premier industrial research and technology organisation in Malaysia, wholly-owned by the Minister​ of Finance Incorporated. With over forty years of experience and expertise, SIRIM is mandated as the machinery for research and technology development, and the national champion of quality. SIRIM has always played a major role in the development of the country’s private sector. By tapping into our expertise and knowledge base, we focus on developing new technologies and improvements in the manufacturing, technology and services sectors. We nurture Small Medium Enterprises (SME) growth with solutions for technology penetration and upgrading, making it an ideal technology partner for SMEs.

PARTNER

HashiCorp provides infrastructure automation software for multi-cloud environments, enabling enterprises to unlock a common cloud operating model to provision, secure, connect, and run any application on any infrastructure. HashiCorp tools allow organizations to deliver applications faster by helping enterprises transition from manual processes and ITIL practices to self-service automation and DevOps practices. 

PARTNER

IBM is a leading global hybrid cloud and AI, and business services provider. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Nearly 3,000 government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and business services deliver open and flexible options to our clients. All of this is backed by IBM’s legendary commitment to trust, transparency, responsibility, inclusivity and service.

Send this to a friend